Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Scientists at IISc have developed hybrid nanoparticles that can kill cancer cells using heat and enable their detection using sound waves. The nanoparticles combine the photothermal and oxidative stress properties of gold and copper sulphide, making them a promising approach for early detection and treatment.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
Researchers discovered that immune cells create local gradients by consuming chemokines, guiding their movement and enhancing directional movement in complex environments. This finding increases understanding of coordinated immune responses and may reveal new strategies for targeting cancer
A new study finds that targeting the ORAI1 calcium channel may provide a promising approach to treating oral cancer. The study reveals that activating this channel causes an influx of calcium into cancer cells, leading to increased pain sensitivity.
Researchers at Case Western Reserve University have identified a new function of the key protein LSD1 that leads to cancer and other diseases. They found that degrading LSD1 rather than just short-circuiting its catalytic activity could be more effective in slowing or stopping cancer growth.
Researchers at Gladstone Institutes identified conditions that enable gamma delta T cells to recognize cancer cells by disrupting energy production and causing cellular stress. This insight suggests that therapies manipulating butyrophilin abundance on the surface of cancer cells could boost gamma delta T cell effectiveness.
Researchers at Cold Spring Harbor Laboratory have made a significant breakthrough in transforming rhabdomyosarcoma cells into regularly functioning muscle cells using differentiation therapy. This innovative approach has the potential to spare patients and their families from pain and suffering by offering a new treatment option.
Scientists have discovered that small fat-filled lipid droplets can indent and puncture a cell's nucleus, leading to elevated DNA damage. This finding has significant implications for various diseases, including cancer.
Researchers developed a new strategy for T-cell-based immunotherapy using aptamers, which directly activates immune cells against cancer cells without genetic modifications. The innovative regulatory circuit establishes an artificial interaction between T cells and cancer cells.
Researchers at Weill Cornell Medicine discovered a new relationship between cancer cells and the immune system, showing how prolonged activation of the STING pathway leads to cellular signaling changes that aid cancer's spread. This finding explains why drugs activating STING have been unsuccessful in clinical trials.
Imperial researchers have imaged Piezo1 channels in human cells and organs, revealing their role in regulating blood pressure, respiration, bladder control, and the immune system. This breakthrough could lead to a better understanding of their role in fundamental physiological processes and potentially new drug targets for diseases.
A new nano-sized force sensor developed by Tampere University researchers allows for the measurement of intracellular forces and mechanical strains. This technology has great potential for studying cancer cells and understanding cellular mechanics.
Researchers have discovered that estrogen promotes tumor growth in ERα-negative cancers, such as triple-negative breast cancer. Anti-estrogenic therapies, when combined with immune checkpoint inhibitors, drastically suppress tumor progression in mice models.
Researchers found a combination of ipilimumab and nivolumab can extend progression-free survival and improve response rates in patients with resistant metastatic melanoma. The treatment showed a 37% improvement in progression-free survival compared to ipilimumab alone.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers find immunotherapy treatment anti-CTLA-4 leads to greater survival in mice with glioblastoma and discover new way cells kill cancer by triggering microglia, specialized immune cells in the brain. This breakthrough could lead to more effective treatments for human brain cancer.
Researchers found that ranolazine, a heart medication, slows down tumor progression and increases visibility of melanoma cells to the immune system. This combination could improve response rates for immunotherapies in patients with melanoma.
A biomolecule has been engineered to selectively target and remove mucins from cancer cells, reducing tumor growth and increasing survival in lab-grown human cancer cells and mouse studies. This discovery could play a significant role in future therapies for cancer, as mucins are associated with many diseases.
Researchers have developed novel liquid metal nanoparticles that combine photothermal therapy with immunotherapy, demonstrating high specificity and low side effects. The nanoparticles can target and destroy cancer cells while also stimulating the immune system to fight against tumors.
A new grant aims to decipher how diverse breast cancer tumors influence cancer cells' ability to resist treatment. By studying this phenomenon, researchers hope to uncover novel targets for more effective therapies.
Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.
Researchers developed a targeted chemotherapy that selectively disrupts DNA replication and repair in cancer cells, leaving healthy cells unaffected. The investigational small molecule AOH1996 has been effective in treating various types of solid tumors in preclinical research.
Researchers at UMass Amherst have discovered a potential new medical therapy for Lyme disease using lactate dehydrogenase inhibitors typically used to combat cancer. The study found that these inhibitors substantially impacted Borrelia burgdorferi growth, making them promising candidates against Lyme infections.
Scientists at Max Delbrück Center discovered two lead compounds that inhibit activation of IKK/NF-κB pathway only when triggered by DNA double-strand breaks. These substances make cancer cells more sensitive to chemotherapy, potentially increasing the success rate of genotoxic cancer therapies.
A breakthrough treatment targeting bone marrow cancer cells destroyed 90% of multiple myeloma cells in laboratory tests and 60% in human tissue samples. Researchers developed lipid-based nanoparticles containing RNA molecules that silence the CKAP5 gene, inhibiting cancer cell division.
Researchers have identified KIAA0930 as a key factor causing muscle atrophy in cancer cells, which could lead to the development of new anti-cachexia therapies. The study found that KIAA0930 knockdown cells showed increased muscle mass and weight compared to control cells.
A new study reveals that cancer cells reprogram normal mesothelial cells into cancer-associated mesothelial cells through the AMH axis, promoting tumor growth and immune evasion. Disrupting this signal slows tumor growth and helps the immune system overcome some of its defenses.
Researchers have identified a new therapeutic target for glioblastoma brain cancer by finding that the 'don't eat me!' signal sent by cancer cells can be blocked using antibodies. This breakthrough suggests that existing immunotherapies may be effective against glioblastomas if the receivers on macrophages are switched off.
A new study by researchers at Dartmouth Cancer Center shows that a combination of estrogen and PARP inhibitors can effectively treat advanced ER+ breast cancer by damaging cancer cells and preventing DNA repair. The treatment strategy has been shown to be effective regardless of BRCA1 or BRCA2 genetic mutations.
Researchers at Nanyang Technological University discover ponatinib, an existing cancer drug, can block key steps in alternative lengthening of telomeres (ALT) mechanism. This could lead to new treatment options for ALT cancers, which currently lack targeted therapies.
Researchers at Nagoya University have discovered three new biomarkers for high-grade serous ovarian carcinoma using membrane proteins and polyketone-coated nanowires. The study reveals that small extracellular vesicles containing these proteins can be used to detect ovarian cancer, potentially leading to personalized medicine.
Researchers have found that PD-L1 triggers signaling that intrinsically alters cancer cell phenotype, impacting immune milieu. The study's findings suggest a new approach to treating patients with limited response to immunotherapy.
Researchers have developed a technology to capture and release cell-free DNA from urine using nanowire surfaces, successfully detecting IDH1 mutation in glioma patients. This method opens possibilities for the detection of other tumor mutations and could revolutionize cancer diagnosis.
Researchers at Tel Aviv University have developed a novel approach to fight cancer by inducing cancer cells to produce a toxic protein using mRNA molecules. The treatment was successful in eliminating 44-60% of cancer cells in animal models, with no damage to healthy cells.
Researchers at Aarhus University have discovered a new method to activate the complement system using bispecific single-domain antibodies, termed BiCEs. These molecules can specifically target cancer cells and activate the complement system, leading to the killing of targeted cancer cells.
Researchers used 3-D models to show that gene activity differs based on a cell's location within a tumor, influencing its role in cancer biology. The study could lead to more precise therapies by targeting specific areas of tumors.
A preclinical study has uncovered the role of Y chromosome gene KDM5D in regulating anti-tumor immune responses and promoting metastasis in male patients with KRAS-mutated colorectal cancer. The study reveals that mutant KRAS drives upregulation of KDM5D, leading to reduced cell adhesion and immune recognition by the immune system.
Researchers found that loss of the Y chromosome in bladder cancer cells allows them to evade the immune system, leading to aggressive growth. However, this loss also renders the disease more responsive to a standard treatment called immune checkpoint inhibitors.
Researchers found that leukemia cells use messenger particles to navigate and release molecular cargo at distant sites, driving cancer metastasis. A potential therapeutic strategy involves targeting these particles with an antibody drug that blocks E-selectin activity.
A team of researchers at Georgetown University's Lombardi Comprehensive Cancer Center has discovered a key role for glucose in regulating DNA synthesis and cancer cell response to chemotherapy. By targeting this pathway, the researchers hope to develop new treatments that make lung cancer more responsive to radiotherapy and chemotherapy.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
Researchers from Universitat de Barcelona and Universitat Internacional de Catalunya discuss the non-receptor protein tyrosine kinase Src as a good example of an oncogene. Targeting the Src N-terminal regulatory element (SNRE) has potential as oncotargets to inhibit Src activity only in cancer cells.
Researchers characterize a unique molecular mechanism in early stages of programmed cell death (apoptosis), a crucial process preventing cancer. By studying Bax protein interactions with mitochondrial lipids, they found that pore creation drives apoptosis initiation.
Cancer cells in brain tumors produce lipids at higher rates than surrounding healthy tissue, offering clues for treatment strategies. The study provides insights into the unique biochemical processes fueling cancer growth in the brain.
The MOSAIC project will use cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution. By analyzing thousands of patient samples, researchers aim to unlock novel cancer treatments and biomarkers through AI-powered analytics.
The nucleus is metabolically active and uses antioxidant enzymes to repair DNA damage. Cells relocate mitochondrial machinery to the nucleus in response to DNA damage, highlighting a paradigm shift in cellular biology.
Researchers developed a novel endoscopic imaging system with a bioinspired sensor that can detect multiple fluorescent probes, enabling more accurate fluorescence-guided cancer surgery. The system showed improved spatial resolution and sensitivity in detecting tumors, paving the way for the adoption of multi-tracer FGS.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers at the University of Gothenburg have developed a method to kill glioblastoma brain tumours by blocking stress in cancer cells. The treatment, which involves inserting a specially developed molecule into cells, shows promising results with no side effects.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
A new Northwestern Medicine study found young adult cancer survivors (18-39 years old) are 2.6 times more likely to develop heart failure when treated with anthracyclines. The incidence is highest among leukemia and other specific cancer types.
A Phase I/II clinical trial combining intratumoral delivery of an engineered oncolytic virus with subsequent immunotherapy improved survival outcomes in a subset of patients with recurrent glioblastoma. The study demonstrated the combination was well-tolerated, with no dose-limiting toxicities.
Researchers created organoids from patient tissues to test chemotherapy drugs and identified genetic signatures that predict treatment response, offering high accuracy in personalized drug screening. This breakthrough may help select effective drugs for individual patients, reducing trial and error.
A new study has provided insight into the mysterious evolution of DNA rings in tumors, revealing that nearly one-third of all tumors have these genetic structures. The researchers used a technology to trace the path of DNA ring development in neuroblastoma cells, finding that large rings contain cancer genes spurring cell growth.
New Finnish studies show that short bouts of light or moderate exercise can increase the number of immune cells capable of destroying cancer cells in cancer patients. The exercises were enough as short as 10 minutes to boost the immune system, with a positive impact on quality of life and prognosis.
Researchers identified copper's role in inflammation and found that it can trigger the expression of genes involved in cancer progression. They also developed a drug prototype called Supformin that blocks copper chemistry, reducing inflammation and cell transformation in cancer cells.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
A research team from the Medical University of South Carolina identified a protein called TACC3 that enables cancer cells to successfully divide despite an abnormality that should lead to their death. This discovery offers new hope for developing targeted therapies to selectively kill cancer cells while leaving normal cells intact.
Researchers propose a new theory on how cancer cells actively adapt to evade the immune system, losing and gaining tumor-associated antigens. This adaptation makes it difficult for immunotherapies to target cancer cells effectively, but may also create new vulnerabilities that can be therapeutically targeted.